Hetrombopag's Efficacy and Security in the Treatment of Thrombocytopenia by Chemotherapy

PANG Lina; GONG Shuai; ZHANG Shengli; ZHANG Xiaoke; WANG Liye; HE Wei

doi:10.3969/j.issn.1004-437X.2023.22.004

Abstract：Objective To retrospectively analyze hetrombopag's efficacy and security in the treatment of thrombocytopenia(CIT)by chemotherapy.Methods The data of malignant tumor chemotherapy combined with CIT ≥2 patients admitted to the hospital from July 2020 to December 2021 were collected and analyzed,and 100 patients who met the inclusion criteria were screened.The patient's gender,age,platelet count(PLT),medication dosage,whether other medication treatments are sequential,and duration of PLT＜75 × 109 L-1,platelet transfusion rate,incidence of adverse reactions were recorded.Results There was no statistically significant difference in the total effective rate of CIT patients with different genders,ages,eastern cooperative oncology group(ECOG)scores,tumor types,CIT grades,and the presence or absence of sequential treatment after(16±3)days of treatment with Hetrombopag(P＞0.05).As time goes on,PLT rebounds to≥100 × 109 L-1 proportion,PLT doubling proportion compared to before treatment,PLT recovery≥20 × 109 L-1 proportion and total effective rate of gradually increased,and the difference was statistically significant(P＜0.001).The total incidence of adverse reactions was 2％,and no thrombosis related events or CIT related bleeding events were found.A total of 4 platelet transfusions were performed during CIT in 100 patients.Conclusion Hetrombopag has a definite therapeutic effect on thrombocytopenia caused by chemotherapy in malignant tumors,with minimal toxic side effects and good patient tolerance.